Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. thrombus formation
Show results for
Products
Services
Software
Training
Applications

Companies


Refine by

Thrombus Formation Articles & Analysis

5 news found

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...

ByBayer AG


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Factor XI is a promising and differentiated target for the development of safer anticoagulants because of its critical role in pathological versus normal thrombus formation uncoupling hemostasis from thrombosis. Patients with congenital Factor XI genetic deficiency demonstrate a lower risk for venous thromboembolism and ischemic stroke but rarely have spontaneous ...

ByBayer AG


TCT 2017 Poster Shows Impact of Strut Thickness on Thrombogenicity in BRS

TCT 2017 Poster Shows Impact of Strut Thickness on Thrombogenicity in BRS

ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the ...

ByArterius Limited


Vesper Medical Announces Completion of Enrollment in the VIVID Clinical Trial

Vesper Medical Announces Completion of Enrollment in the VIVID Clinical Trial

CVI can manifest in multiple ways, the most severe forms resulting in skin changes and ulcers, leading to poor quality of life for patients as well as life threatening complications like acute deep vein thrombus formation.2 “The rapid enrollment of the VIVID Trial is a testimonial to the magnitude and severity of chronic venous insufficiency and the ...

ByVesper Medical, Inc.


Second Heart Assist Announces Successful Completion of Long-Duration Pre-Clinical Studies

Second Heart Assist Announces Successful Completion of Long-Duration Pre-Clinical Studies

We are particularly excited about the excellent outcomes we saw during long-duration studies where we noted minimal hemolysis and only minor clinically insignificant thrombus formation after over 40 hours of operation.” Richardson further stated, “These studies, again, give evidence to the advantages of the unique design for our catheter-based ...

BySecond Heart Assist, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT